ACADEMIA

Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi

By Tomohiro Osakabe January 22, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Pharma companies are vying to develop the next Alzheimer’s disease (AD) treatments that would follow Eisai’s Leqembi (lecanemab). Eli Lilly has a similar drug under regulatory review, while Roche is pursuing a compound with a novel brain delivery model. Top…

To read the full story

As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
August 9, 2024

ACADEMIA

Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

TSE’s Growth Market Reform Puts Pressure on Biotechs

By Tatsuya Otsuka

Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…